Tall cell carcinoma with reversed polarity: A case report of a very rare breast tumor entity and mini‐review

2021 ◽  
Vol 27 (4) ◽  
pp. 369-376
Author(s):  
Helen J. Trihia ◽  
Pavlos Lampropoulos ◽  
Loukas Karelis ◽  
Efthymia Souka ◽  
Georgios Galanopoulos ◽  
...  
2020 ◽  
Vol 47 (6) ◽  
pp. 4917-4921
Author(s):  
Simon Haefliger ◽  
Simone Muenst ◽  
Philip Went ◽  
Michel Bihl ◽  
Sophie Dellas ◽  
...  

Pathology ◽  
2021 ◽  
Vol 53 ◽  
pp. S30-S31
Author(s):  
Anurita Kar ◽  
Fouzia Ziad

Gland Surgery ◽  
2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Yufan Wei ◽  
Liming Ding ◽  
Xin Song ◽  
Xia Tian ◽  
Ningning Min ◽  
...  

2020 ◽  
Vol 7 (1) ◽  
pp. 46
Author(s):  
Kaitlyn J Nielson ◽  
Edgar G. Fischer ◽  
Jacklyn Jacklyn Nemunaitis ◽  
Sangeetha Prabhakaran ◽  
Nadja K. Falk

Breast tall cell carcinoma with reversed polarity (TCCRP) is rare and previously referred to as solid papillary carcinoma with reverse polarity.  This low grade tumor commonly exhibits IDH2 p.Arg172 mutation, however is not completely understood at the molecular level.  We present a case of TCCRP in a 55 year old woman with a 0.7 cm left breast mass.  A core biopsy was performed with immunohistochemistry.  Lumpectomy and sentinel lymph node biopsy were completed two months later.  MammaPrint$^{\textregistered}$ and BluePrint$^{\textregistered}$ gene expression profilers were performed on an excision block.  Microscopically, the tumor was composed of circumscribed nests of columnar cells, with focal papillary architecture.  Tumor cells had apically located nuclei with grooves and rare inclusions. Tumor cells were positive for CK5, IDH1/2, and calretinin, and myoepithelial cells were absent.  BluePrint$^{\textregistered}$ subtyped the tumor as basaloid.  MammaPrint$^{\textregistered}$ classified the tumor as high risk for metastasis.  TCCRP presents a diagnostic challenge.  Although these rare breast carcinomas are generally reported to have an indolent clinical course, molecular analysis by gene expression profiling classified this tumor as high risk of recurrence with a basaloid type.  Therefore, molecular analysis of this tumor may lead to conflicting data regarding prognosis and treatment considerations.  Clinicians and patients should weigh published data and individual prognostic information for treatment planning.  Our patient and clinical team opted for radiation without chemotherapy.  More cases of TCCRP need to be studied to better understand its molecular profile.


Gland Surgery ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 837-843
Author(s):  
Xiaohui Zhang ◽  
Huanwen Wu ◽  
Zhe Wang ◽  
Yidong Zhou ◽  
Feng Mao ◽  
...  

2006 ◽  
Vol 14 (1) ◽  
pp. 79-84 ◽  
Author(s):  
J. Cameselle-Teijeiro ◽  
I. Abdulkader ◽  
F. Barreiro-Morandeira ◽  
C. Ruiz-Ponte ◽  
R. Reyes-Santias ◽  
...  

2015 ◽  
Vol 4 (2) ◽  
pp. 129-132 ◽  
Author(s):  
Luca Gordini ◽  
Francesco Podda ◽  
Fabio Medas ◽  
Maria Letizia Lai ◽  
Alessandro Longheu ◽  
...  

Cureus ◽  
2021 ◽  
Author(s):  
Gustavo Matute ◽  
Linda Barcenas ◽  
Carolina Bautista ◽  
Carlos Alberto Restrepo Ramirez ◽  
Nestor Llinas Quintero

1994 ◽  
Vol 30 (2) ◽  
pp. 309
Author(s):  
Sin Young Cho ◽  
Chul Soon Choi ◽  
Ell Seong Lee ◽  
Hyeun Cha Cho ◽  
Eun Young Kwack ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document